|
The Role of CD34+ Stem Cells in the Pathogenesis of Takotsubo Syndrome
RECRUITINGSponsored by University Medical Centre Ljubljana
Actively Recruiting
SponsorUniversity Medical Centre Ljubljana
Started2021-09-06
Est. completion2026-06-30
Eligibility
Age18 Years+
Healthy vol.Accepted
View on ClinicalTrials.gov →
NCT07604467
Summary
The underlying mechanisms of microvascular dysfunction in Takotsubo cardiomyopathy remain incompletely understood. As CD34+ cells are essential to coronary microvascular homeostasis we will investigate the potential association between CD34+ cell count and changes in left ventricular function in patients with Takotsubo cardiomyopathy at baseline and 6-month follow-up.
Eligibility
Age: 18 Years+Healthy volunteers accepted
Inclusion Criteria: * Minimum age 18 years * Established TTS per InterTak registry criteria * Signed consent form Exclusion Criteria: * Patients under the age of 18 years * Ischemic heart disease with at least one complete total occlusion * Other concurrent cardiomyopathies * Active infectious myocarditis * obstructive coronary artery disease * Previous hospital stay due to acute coronary syndrome (myocardial infarction) in the last 6 months before TTS acute event * Previous interventional coronary artery procedure in the last 6 months before TTS acute event * Significant valvular heart disease * Significant peripheral artery occlusive disease * Active or remitted hematologic malignancy * Patients receiving immunosuppressive therapy * Significant comorbiditeis affecting patients survival (malignancy) * Failure to obtain freely given, informed consent form.
Conditions6
CD34+ Stem CellsCardiac Contractility RecoveryHeart DiseaseHeart FailureMicrovascular DysfunctionTako Tsubo Cardiomyopathy
Browse More Trials
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.
Actively Recruiting
SponsorUniversity Medical Centre Ljubljana
Started2021-09-06
Est. completion2026-06-30
Eligibility
Age18 Years+
Healthy vol.Accepted
View on ClinicalTrials.gov →
NCT07604467